The Diagnostic Performance of 68Ga-PSMA-11 PET/MRI for the Biochemically Recurrent Prostate Cancer: A Systematic Review and Meta-analysis
D Wang, ZH Wang, CB Wang, ZC Wu - Iranian Journal of Public …, 2024 - ijph.tums.ac.ir
Background: Our meta-analysis aimed to evaluate the diagnostic performance of 68 Ga-
PSMA-11 PET/MRI for biochemical recurrence of prostate cancer. Methods: We …
PSMA-11 PET/MRI for biochemical recurrence of prostate cancer. Methods: We …
Whole-body tumour burden on [18F] DCFPyL PET/CT in biochemical recurrence of prostate cancer: association with tumour biology and PSA kinetics
L García-Zoghby, M Amo-Salas… - European Journal of …, 2024 - Springer
Purpose The objective was to assess the association between molecular imaging (mi)
variables on [18F] DCFPyL-PET/CT with clinical and disease characteristics and prostate …
variables on [18F] DCFPyL-PET/CT with clinical and disease characteristics and prostate …
To evaluate the detection rate of local and whole-body recurrence by integrated [18F] F-PSMA-1007 PET/MR assessment of prostate cancer patients treated with …
JR Garcia, A Compte, J Pastor, S Mourelo… - Revista Española de …, 2024 - Elsevier
Objective To analyse the efficacy of integrated assessment of [18 F] F-PSMA-1007 PET/MRI
on the early detection of local recurrence (LR) for prostate cancer patients with PSA levels< …
on the early detection of local recurrence (LR) for prostate cancer patients with PSA levels< …
18F-FDG PET/CT as a molecular biomarker in the diagnosis of amyotrophic lateral sclerosis associated with prostate cancer and progressive supranuclear palsy: A …
EA Cortés Mancera, FA Sinisterra Solis… - Frontiers in Nuclear …, 2023 - frontiersin.org
Introduction Amyotrophic lateral sclerosis (ALS) is a neurodegenerative, multisystem
disorder. Its clinical presentation typically consists of progressive focal muscle atrophy and …
disorder. Its clinical presentation typically consists of progressive focal muscle atrophy and …
[PDF][PDF] Evaluating the Initial Experience and Clinical Impact of Prostate-Specific Membrane Antigen (PSMA) Positron Emission Tomography/Computed Tomography …
LR Sulaiman - Cureus, 2024 - cureus.com
Background Prostate cancer is a significant health concern globally, especially in the Middle
East, including Iraq. This study explores the adoption and impact of prostate-specific …
East, including Iraq. This study explores the adoption and impact of prostate-specific …
Evaluación de la tasa de detección de la recidiva local y de cuerpo completo mediante la valoración integrada de la PET/RM con [18F] F-PSMA-1007 de pacientes …
JR Garcia, A Compte, J Pastor, S Mourelo… - Revista Española de …, 2024 - Elsevier
Objetivo Analizar la eficacia de la valoración integrada [18 F] F-PSMA-1007 PET/RM en la
detección precoz (PSA< 0, 5 ng/ml) de la recidiva local (RL) tras prostatectomía. Evaluar la …
detección precoz (PSA< 0, 5 ng/ml) de la recidiva local (RL) tras prostatectomía. Evaluar la …
[HTML][HTML] Re-irradiation to the prostate using stereotactic body radiotherapy (SBRT) after initial definitive radiotherapy–A systematic review and meta-analysis of recent …
C Schröder, H Tang, B Lenffer, A Buchali… - Clinical and …, 2024 - Elsevier
Background There is increasing data on re-irradiation to the prostate using stereotactic body
radiotherapy (SBRT) after definitive radiotherapy for prostate cancer, with increasing …
radiotherapy (SBRT) after definitive radiotherapy for prostate cancer, with increasing …